Status:
UNKNOWN
Circulating Tumor DNA as Marker for Response to Antineoplastic Treatment of Metastatic Cancer (FLUIDO)
Lead Sponsor:
Elisabethinen Hospital
Collaborating Sponsors:
Medical University Innsbruck
Conditions:
Metastatic Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Early monitoring of antineoplastic treatment benefit is a central medical need. Radiologic assessment for documentation of response is done after several months of treatment usually. This implies that...
Detailed Description
Patients Patients with metastatic cancer who are treated with antineoplastic treatment are eligible if a molecular marker is either known due to the type of cancer (Case A) or if a molecular marker is...
Eligibility Criteria
Inclusion
- Metastatic cancer (mPDAC, mGC, mCRC)
- Known mutation of the cancer
- Signed informed consent
- At least 18 years
- Eligible for antineoplastic treatment
Exclusion
- o Inclusion criteria not met
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04793061
Start Date
April 1 2021
End Date
November 30 2022
Last Update
March 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ordensklinikum Linz
Linz, Upper Austria, Austria, 4020